TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03373968: Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Sponsor: Italfarmaco · Phase: PHASE2/PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 206 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,837,910

Rescue Site Savings

+$3,204,330

Unlock Full NCT03373968 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03373968 Rescue Dossier →